

***JERRY BAGEL, M.D., M.S.***  
**East Windsor Professional Park**  
**59 One Mile Road Extension**  
**East Windsor, NJ 08520**  
**(609) 443-4500 / Fax: (609) 443-4030**  
**Psoriasisicare.com / Dreamacres1@aol.com**

**PSORIASIS TREATMENT CENTER**

1985 – Present Director, Psoriasis Treatment Center of Central New Jersey.  
Facilities include Broad band UVB, PUVA, narrow band UVB, hand/foot phototherapy, systemic therapy, biological therapy, excimer laser and clinical trials.

**EDUCATION AND TRAINING**

1985 – Present Private Practice, Clinical Dermatology  
1982 – 1985 Dermatology Resident  
College of Physicians and Surgeons – Columbia University  
1981 – 1982 Internship in Internal Medicine – Jackson Memorial Medical Center  
University of Miami – School of Medicine  
1981 M.D. Mt. Sinai School of Medicine  
1977 M.S. in Biochemistry – Rutgers University  
1975 B.A. cum laude in Biology – Boston University  
1971 Graduated Salutatorian – Hightstown High School

**LICENSURE**

1985 Board Certification in American Board of Dermatology  
1985 New Jersey Medical License #25MA04445900

**CLINICAL TRIALS**

2018 A Study to Evaluate the Safety and Efficacy of Brodalumab in Subjects with Moderate to Severe Plaque Psoriasis Who Have Failed IL-17A Therapies. Sponsored by Icahn School of Medicine at Mount Sinai.

2018 Skin Biopsy Analysis for Inflammatory Skin Disorders. Sponsored by Jerry Bagel, MD.

2018 A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Pruritis in Adults with Plaque Psoriasis. Sponsored by Menlo Therapeutics.

- 2017 CC-10004-SPSO-001 A Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis of the Scalp (STYLE). Sponsored by Celgene
- 2017 Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 2 (ECZema TRAlokinumab Trial no. 2) (ECZTRA 2) Sponsored by LEO Pharma.
- 2017 Safety, Efficacy, and Tolerability of SNA-120 in Subjects With Pruritus Associated With Psoriasis Vulgaris. Sponsored by Sienna Biopharmaceuticals
- 2017 A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on AK on Face or Scalp (AK003). Sponsored by Athenex, Inc.
- 2017 A Study to Evaluate the Safety and Efficacy of CLS006 Versus Vehicle in Subjects 2 Years of Age or Older With Cutaneous Common Warts Sponsored by Cutanea Life Sciences, Inc.
- 2017 An Open-Label, Pilot Study to Evaluate the Efficacy of Narrowband Ultraviolet-B Phototherapy Three Times Weekly for Twelve Weeks in Moderate-to-Severe Psoriasis Patients. Sponsored by Psoriasis Treatment Center of Central New Jersey
- 2017 A Study to Evaluate the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis (ECLIPSE). Sponsored by Janssen Research & Development, LLC
- 2017 Enstilar in Combination With Biologic Agents. Sponsored by Psoriasis Treatment Center of Central New Jersey.
- 2017 A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis (LIMMITLESS). Sponsored by AbbVie.
- 2017 A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to Explore changes in Subcutaneous Adipose Tissue and Modulation of Skin Inflammation After 12 Weeks of Treatment with Secukinumab, Compared to Placebo, and Up to 52 Weeks of Treatment with Secukinumab in Adult Patients with Moderate to Severe Plaque Psoriasis. Sponsored by Novartis.
- 2017 A Phase 2A, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate Safety and Efficacy of PF-06700841 in Subjects with Moderate to Severe Plaque Psoriasis. Sponsored by Pfizer.

- 2017 An Open-Label, Observational Study Evaluating Enstilar (calcipotriene and betamethasone dipropionate) Foam, 0.005%/0.064% QD in Psoriasis Patients Being Treated with Biologic Agents. Sponsored by Jerry Bagel.
- 2017 An Open-Label, Randomized, Actual Use Study of Dupilumab Auto-Injector Device in Patients with Atopic Dermatitis. Sponsored by Regeneron
- 2017 Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of Ixekizumab in Patients from 6 to Less than 18 Years of Age with Moderate-to-Severe Plaque Psoriasis. Sponsored by Eli Lilly and Company.
- 2017 LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris. Sponsored by LEO Pharma A/S.
- 2016 A Randomised, Double-blind, Vehicle-Controlled, Phase IIb Study to Assess the Efficacy and Safety of Topically Applied DS107 Cream to Adults with Mild to Moderate Atopic Dermatitis. Sponsored by DSBiopharma.
- 2016 A Phase 2b Multicenter, Randomized, Placebo-Controlled, Double-Blind Dose-Ranging Study to Evaluate ABT-494 in Adult Subjects with Moderate to Severe Atopic Dermatitis. Sponsored by Abbvie
- 2016 A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multiple-Site Study to Evaluate the Therapeutic Equivalence of a Generic Pimecrolimus Cream 1% (Glenmark Pharmaceuticals Ltd) to the Marketed Product Elidel (pimecrolimus) Cream 1% (Valeant Pharmaceuticals North America LLC) in the Treatment of Mild to Moderate Atopic Dermatitis. Sponsored by Glenmark Pharmaceuticals Ltd.
- 2016 A Phase 2, Multicenter, Randomized, Parallel-Arm, Placebo-Controlled Study of LY3074828 in Subjects with Moderate-to-Severe Plaque Psoriasis. Sponsored by Eli Lilly.
- 2016 A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose Finding Study to Evaluate the Safety, Tolerability and Efficacy of KD-025 in Adult Subjects with Moderate to Severe Chronic Plaque Psoriasis who are Candidates for Systemic Therapy or Phototherapy. Sponsored by Kadmon.
- 2016 2016 A Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of LYC-30937-EC in Subjects with Moderate Chronic Plaque Type Psoriasis. Sponsored by Lycera Corp.
- 2016 A 52-Week, Multi-Center, Randomized, Double-Blind, Study of Secukinumab (300mg) to Demonstrate Efficacy as Assessed by Psoriasis Area and Severity Index and Investigators Global Assessment After 12

- Weeks of Treatment, Compared to Ustekinumab, and to Assess Long-Term Safety, Tolerability, and Efficacy in Subjects with Moderate to Severe Plaque Psoriasis. Sponsored by Novartis.
- 2016 An Open-Label, Observational Study Evaluating Topicort Topical Spray 0.25% (desoximetasone) in Patients with Scalp Psoriasis. Sponsored by Jerry Bagel.
- 2016 Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects with Moderate to Severe Plaque Psoriasis Who Have Failed Therapy with Apremilast. Sponsored by Amgen
- 2016 A Phase IIB, Randomized, Double-Blind, Randomized, Placebo Controlled, Parallel, Multicenter, Dose Ranging, Study To Evaluate the Efficacy and Safety Profile of PF-04965842 in Subjects with Moderate to Severe Atopic Dermatitis. Sponsored by Pfizer.
- 2016 Concept Elicitation, Cognitive Debriefing, and Usability Testing in Chronic Plaque Psoriasis. Sponsored by Endpoint.
- 2016 A PROspective, observational, US-based study assessing outcomes, adverse events, treatment patterns, and quality of life in patients diagnosed with mycosis fungoides cutaneous T-cell lymphoma and treated with Valchlor. Sponsored by Actelion.
- 2016 An Open-Label, Observational Study Evaluating Topicort Topical Spray 0.25% (desoximetasone) BID in Psoriasis Patients Being Treated with Biologic Agents. Sponsored by Jerry Bagel
- 2015 Corrona Psoriasis Registry. Sponsored by Corrona, LLC
- 2015 A Phase III, Multi-Center, Double-Blind, Randomized, Vehicle Controlled Clinical Study To Assess the Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis. Sponsored by Dow Pharmaceutical Sciences.
- 2015 A Phase III, Multi-Center, Open Label Study to Evaluate the Long-Term Safety of IDP-118 Lotion in the Treatment of Plaque Psoriasis. Sponsored by Dow Pharmaceutical Sciences.
- 2015 A Multi-Center, Randomized, Double-Blind Study Comparing the Efficacy and Safety of Ixekizumab Dosing Regimens in Patients with Moderate-to-Severe Plaque Psoriasis. Sponsored by Eli Lilly and Company.
- 2015 An Open Label Extension Trial Assessing the Safety and Efficacy of BI 655066 Administered Subcutaneously in Patients with Moderate to Severe Chronic Plaque Psoriasis. Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc.
- 2015 A Prospective, Observational, US-Based Study Assessing Outcomes, Adverse Events, Treatment Patterns, and Quality of Life in Patients

- Diagnosed with Mycosis Fungoides Cutaneous T-Cell Lymphoma and Treated with Valchlor. Sponsored by Actelion Pharmaceuticals US, Inc.
- 2015 A Phase IV, Multi-Center, Randomized, Placebo-Controlled, Double-Blind, Study of the Efficacy and Safety of Apremilast (CC-10004), in Subjects with Moderate Plaque Psoriasis. Sponsored by Celgene Corporation.
- 2015 An Open-Label Study of Dupilimab in Patients with Atopic Dermatitis who participated in Previous Dupilimab Clinical Trials. Sponsored by Regeneron Pharmaceuticals, Inc.
- 2015 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Investigating the Efficacy and Safety of Multiple Dupilimab Dose Regimens Administered as Monotherapy For Maintaining Treatment Response in Patients with Atopic Dermatitis. Sponsored by Regeneron Pharmaceuticals, Inc.
- 2015 Single-Center, Two Phase, Pilot Study to Evaluate the Efficacy and Safety of Combining Otezla® (apremilast) 30mg BID in Combination with Narrowband UVB (nUVB) Phototherapy, to Determine Effectiveness of Otezla® in Promoting Maintenance of Response in the Treatment of Moderate-to-Severe Plaque Psoriasis. Sponsored by Jerry Bagel, MD
- 2015 Randomized, Phase 2, Double-Blind, Vehicle-Controlled Trial to Evaluate the Safety and Efficacy of Q301 Cream in Patients with Moderate to Severe Atopic Dermatitis. Sponsored by Qurient
- 2014 A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilimab Monotherapy Administered to Adult Patients with Moderate-To-Severe Atopic Dermatitis. Sponsored by Regeneron Pharmaceuticals, Inc.
- 2014 A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Group, Study Followed by A Dose-Blind and Open-Label Follow-Up to Evaluate the Efficacy and Safety of Certolizumab Pego in Subjects with Moderate to Severe Chronic Plaque Psoriasis. Sponsored by UBC Biopharma, SPRL
- 2014 A Phase 3, Multicenter, Randomized, Double-Blind, Placebo and Active Comparator-Controlled Study Evaluating the Efficacy and Safety of Guselkumab for the Treatment of Subjects with Moderate to Severe Plaque-Type Psoriasis. Sponsored by Janssen Research & Development, LLC
- 2014 A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Demonstrate the Efficacy of Subcutaneous Secukinumab [300mg] as Assessed by the Psoriasis Scalp Severity Index (PSSI) at 12 Weeks of Treatment, Compared to Placebo, and Assess Safety and Tolerability Up to 24 Weeks in Adult Subjects with Moderate to Severe Scalp Psoriasis. Sponsored by Novartis Pharmaceuticals Corporation

- 2014 Characterization of Chronic Inflammatory Skin Disease. Sponsored by TRBIO
- 2014 A Small Methods Study Involving Electronic Data Collection in Normal Care Settings with Adult Psoriasis Patients Who Have A High Level of Clearance (As Determined by sPGA of 0 or 1) And Are Currently Being Treated With A Biologic. Sponsored by HRA
- 2014 LEO 90100 Aerosol Foam Compared to Calcipotriol Plus Betamethasone Dipropionate Gel in Subjects with Psoriasis Vulgaris. Sponsored by Leo Pharma
- 2014 A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle-Controlled Clinical Study to Assess the Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis. Sponsored by Valeant
- 2014 A Phase 3, Multicenter, Double-Blind, Randomized, Parallel-Arm, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Adalimumab for Treatment of Nail Psoriasis in Subjects with Chronic Plaque Psoriasis. Sponsored by AbbVie
- 2014 A 52-week, multicenter, randomized, double-blind study of subcutaneous secukinumab to demonstrate efficacy as assessed by Psoriasis Area and Severity Index at 16 weeks of treatment compared to ustekinumab and to assess long-term safety, tolerability and efficacy in subjects with Moderate to severe plaque psoriasis. Sponsored by Novartis
- 2014 A 48 weeks study of three different dose regimens of BI 655066 Administered subcutaneously in patients with moderate to severe Chronic plaque psoriasis (randomized, dose-ranging, active-comparator controlled (ustekinumab), double-blind within dose groups of BI 655066). Sponsored by Boehringer Ingelheim
- 2013 A Multicenter, Randomized, Double-Blind, Parallel Group Comparison of Halobetasol Propionate Lotion 0.05% Versus Vehicle Lotion in Subjects with Plaque Psoriasis. Sponsored by Therapeutics Inc.
- 2013 An Observational Study to Assess Patient Satisfaction and Control of Psoriasis with Taclonex® Topical Suspension and Effect on Quality of Life. Investigator Sponsored.
- 2013 A Randomized, Double-Blind, Vehicle-Controlled, Multicenter, Parallel Group Study of the Safety of Betamethasone Dipropionate Spray 0.05% versus Diprolene® (augmented betamethasone dipropionate) Lotion 0.05% and the Efficacy of Betamethasone Dipropionate Spray 0.05% versus Vehicle Spray in the Treatment of Moderate Plaque Psoriasis. Sponsored by Promius

- 2013 A Randomized, Vehicle-Controlled, Double-Blind, Parallel-Group, Multi-Center Phase III Study to Evaluate the Safety and Efficacy of the Investigational Drug in Plaque Psoriasis Patients. Sponsored by Maruho
- 2013 Eli Lilly: A 12-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of LY2439821 to Etanercept and Placebo in Patients with Moderate to Severe Plaque Psoriasis with a Long-Term Extension Period
- 2013 Eli Lilly: Pharmacokinetic Evaluations of Ixekizumab following Subcutaneous Administration Using Prefilled Syringe or Auto-Injector in Patients with Moderate-to-Severe Plaque Psoriasis
- 2012 Janssen Biotech: A Phase 3b, Randomized, Double-Blind, Active-controlled, Multicenter Study to Evaluate a “Subject-tailored” Maintenance Dosing Approach in Subjects with Moderate-to-Severe Plaque Psoriasis
- 2012 Eli Lilly: Phase 2b A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2b Study of LY3009104 in Patients with Moderate-to-Severe Plaque Psoriasis
- 2011 Amgen: A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects with Moderate to Severe Plaque Psoriasis: AMAGINE-3
- 2011 Amgen: Open Label Study to evaluate the efficacy and safety of Entanercept Treatment in Subjects with Moderate to Severe Plaque Psoriasis Who Have Lost a Satisfactory Response to Adalimumab
- 2011 Galderma: A Multicenter, Randomized, Double-Blind, Vehicle-Controlled Parallel Group Study to Demonstrate The Efficacy and Assess The Safety of CD07805/47 Gel 0.5% Applied Topically Once Daily in Subjects with Moderate to Severe Facial Erythema Associated With Rosacea.
- 2011 Anterior Hyperhidrosis: To Evaluate Sweat Production in Subjects With Primary Axillary Hyperhidrosis in Adults.
- 2011 Prometheus: Collection of Blood Samples for Developing Assays to measure Drug Levels and Anti-Drug Antibody Levels in Subjects treated with Humira
- 2011 No compounds 04001: A Multicenter, Observational, Non interventional, Narrative Study to Evaluate Patient-reported Experiences of Living with Moderate to Severe Plaque Psoriasis
- 2010 Celgene: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Apremilast (Cc-10004) In Subjects with Mild to Severe Plaque Psoriasis

|                |  |
|----------------|--|
| 2010           | Vitiligo: A Single Center, Single-Arm, Open-Label, Pilot Trial to Evaluate The Safety, Effectiveness, and Impact on Quality of Life. Adalimumab Treatment in Adults with Stable Generalized Vitiligo Vulgaris  |
| 2010           | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Adding Methotrexate to Entercept in Subjects with Moderate to Severe Plaque Psoriasis  |
| 2009 – Present | Effectiveness and Safety of 3 Dosing Regimens of CP – 690, 550 to Placebo in Subjects with Moderate to Severe Chronic Plaque Psoriasis sponsored by Pfizer   |
| 2009 – Present | Moderate to Severe Plaque Psoriasis with Scalp Involvement_sponsored by Amgen  |
| 2009 – Present | Trial to Evaluate the Effectiveness and Safety of HUMIRA in Combination with Narrowband UVB (NB-UVB) Phototherapy for the Treatment of Psoriasis sponsored by Abbott   |
| 2009           | A Controlled Study of Humira in Subjects with Chronic Plaque Psoriasis of Hands and/or Feet  |
| 2009           | Esprit Registry  |
| 2008           | Psolar Registry  |
| 2007           | Observe Registry   |
| 2008           | Abbott Protocol M06-890: Phase III: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled study comparing the Safety and Efficacy to Two Regimens of ABT-874 to placebo in subjects with moderate to severe chronic plaque psoriasis  |
| 2008           | Genentech Protocol ACD4412n: A Phase IV Randomized Double-Blind Placebo Controlled Study to Evaluate The Safety and Efficacy of 1.0 Mg/Kg EFALIZUMAB In Adult Patients with Moderate to Severe Plaque Psoriasis with The Involvement of The Scalp.   |
| 2008           | Atlanta Protocol 0416-01-01: A multi-Center Double-Blind, Randomized, Vehicle Controlled, Parallel-Group Study Comparing Altana Inc's Tacrolimus ointment 0.1% to Protopic (Tacrolimus) Ointment 0.1% and Both Active Treatments to a Vehicle Control in the Treatment of Atopic Dermatitis. |
| 2007           | A Single-Center, Prospective, Single-Blind, Pilot Study to Compare the Effect of Diet in Overweight or Obese Patients with Psoriasis on Light Therapy.   |



2007 A Clinical Evaluation of Safety and Efficacy of Adding Topical Coal Tar Solution to Standard UVB Phototherapy Administered 3 Times Weekly to Patients with Generalized Psoriasis: a Pilot Study.

2007 A Comparative Pharmacokinetic Evaluation of 4% Trade Name (Fluorouracil) Cream Vs Efudex Cream in Patients with Actinic Keratosis: Hill Dermaceuticals Inc.

2005-06 A Phase 3 Multi-centered, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Efficacy and Safety of CNTO 1275 in the Treatment of Subjects with Moderate to Severe Plaque-Type Psoriasis: Centocor, Inc.

2005-06 A Phase III, Long-term, Open Label Study to Evaluate the Safety of Twice-daily Tacrolimus Cream-B in the Treatment of Psoriasis: Astellas, Inc.

2005 A Multicenter, Open-label, Pilot Trial to Evaluate the Effectiveness and Safety of Enbrel in Combination with narrowband UVB Phototherapy for the Treatment of Psoriasis: Amgen, Inc.

2005 Safety and Efficacy Evaluation of Tretinoin Gel, 0.05% versus Tretinoin Gel Vehicle in the Treatment of Mild to Moderate Acne Vulgaris: Healthpoint, Ltd.

2005 Point in Time Collection Protocol in Order to Build a Repository of DNA Specimens from Donor/Participants with Genetic and Clinical Signs of Psoriasis with a matched Control Group: BioCollections, Inc.

2004 Atlas Registry

2004 Phase IV Psoriasis Study to Evaluate Safety and Efficacy of an Extended Course of Alefacept, following a Standard 12-Week Course of Amevive: Biogen, Idec.

2004 Phase II Psoriasis Study Evaluations STA S326: Synta Pharmaceuticals

2004 Phase II Psoriasis Study Evaluating Psoraxine/AS210: Astralis, Inc.

2004 Phase 3b Psoriasis Study Evaluating Etanercept: Amgen, Inc.

2004 Phase II Psoriasis Study Evaluating CNTO 1275: Centocor, Inc.

2004 Phase III Psoriasis Study Evaluating 0.3% FK506 Gel vs. Gel Vehicle: Fujisawa Healthcare, Inc.

2003 Phase 1 Psoriasis Study Evaluating IM AS210 in Moderate Psoriasis: Astralis, Ltd.

2004 SQ IL-12 Monoclonal Antibody in Psoriasis: Centocor

2003 Alefacept in Psoriatics Weighing Between 100kg –150kg: Biogen

2003 SQ Enbrel 50mg BIW in Moderate to Severe Psoriasis.

2003 CD4 Antibody Study in Patients with Moderate to Severe Psoriasis: Genmab

2003 Tuporal Capsules in Patients with Moderate to Severe Psoriasis: Stifle Laboratory

2002 A Phase 2, Randomized, Double-Blind Study of 0.1% and 0.5% Tacrolimus Cream Versus Cream Vehicle in the Treatment of Mild to Moderate Plaque Psoriasis in Adults: Fujisawa

2002 SQ ENBREL in Moderate to Severe Psoriasis: Amgen

2002 B-Clear in Localized Psoriasis: Lumenis

2002 Calcitrol 3ug/g Ointment in Psoriasis; Galderma

2001 A Two-Part, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Clinical Trial of ABX-IL8 in Patient with Moderate to Severe Plaque Psoriasis: Abgenix

2001 A Phase 2, Randomized, Double-Blind Study of 0.3% Tacrolimus Gel versus Gel Vehicle in The Treatment Of Mild to Moderate Psoriasis in Adult Subjects: Fujisawa

2001 A Randomized, Double-Blind, Parallel Group Evaluation of Clobetasol Propionate Shampoo, 0.05% versus Its Vehicle – An Efficacy and Safety Study in Subject with Scalp Psoriasis: Galderma

2000 Phase II Psoriasis Study; Evaluating PVAC: Corixa

2000 Phase II Psoriasis Study; Evaluation topical FK8453 Gel: Fujisawa

2001

2000 Phase III Psoriasis Study; evaluating subcutaneous anti-CD11a: Genentech

1999 Evaluate safety of Topical Tacrolimus Ointment for the Treatment of Atopic Dermatitis: Fujisawa

1999 Evaluate Safety and Efficacy of Tazarolene Cream 0.1% in Acne: Allergan

1999 A Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle – Controlled Study of The Efficacy and Safety of Fluticasone Propionate Lotion 0.05% Applied Once Daily for Four Weeks in the Treatment of

- Adult and Pediatric Subjects with Moderate to Severe Atopic Dermatitis (with GlaxoWellcome).
- 1998-2002 Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Response Study of BG9273 in subjects with Moderate to Severe Plaque Psoriasis (with Biogen).
- 1998 Multicenter, Double-Blind, Randomized, Vehicle-Controlled, Study of the Safety and Efficacy of 0.05% and 0.1% Tazarotene Creams applied once daily for 12 weeks in the Treatment of Plaque Psoriasis (with Allergan).
- 1997 A Double-Blind, Randomized, Parallel Study Comparing Two Formulations of 12% Ammonium Lactate Lotion and a Placebo for the Treatment of Ichthyosis Vulgaris (with Clay Park Labs).
- 1998
- 1996 L-733, 725 Multiple Oral Dose Safety, Tolerability, and Biological Activity Study in Psoriatic Patients (with Merck Pharmaceutical).
- 1997
- 1995 & 1997 Phase II of a Double Blind, Placebo-Controlled, Randomized, Trial of DAB389IL-2 in Patients with Moderate to Severe Plaque Psoriasis (with Seragen Pharmaceutical).
- 1993 – 1994 A Double Blind, Placebo-Controlled, Randomized, Parallel Group Study to Evaluate the Effects of Cyclosporine a on an Ex-Vivo Stimulation Assay and on a Calcineurin Phosphatase Assay In Patients with Chronic Plaque Psoriasis (With Merck Pharmaceutical).

### **PUBLICATION**

- 2018 Bagel, J., M.D. & Stein Gold, L. et al. Efficacy and Safety of Apremilast in Systemic- and Biologic-Naïve Patients With Moderate Plaque Psoriasis: 52-Week Results of UNVEIL, JDD 2018 Feb. Vol. 17, Issue 2 pp. 221-228.
- 2018 Bagel, J., M.D., Transitioning Biologic and Systemic Therapies in Psoriatic Patients, Ch. 24 pp 241-245, Yamauchi, Paul S., Editor, Biologic and Systemic Agents in Dermatology; 24 pp 241-245.
- 2017 Bagel, J. & Stein Gold, L. Combining Topical Psoriasis Treatment to Enhance Systemic and Phototherapy Regimens: A Review of the Literature. JDD 2017; 16 pp 611-624.
- 2017 Bagel, J. et al. Secukinumab moderate to severe psoriasis on scalp: JAAD. 2017; 77 pp 659-667.
- 2017 Bagel, J, Callis Duffin, K, Moore, A, Ferris, L. K., Siu, K, Steadman, J, Kianifard, F., Nyirady, J., Lebwohl, M. The Effect of Secukinumab on Moderate-to-Severe Scalp Psoriasis: Results of a 24-Week, Randomized,

Double-blind, Placebo-controlled Phase 3b Study. *J Am Acad Dermatol*. 2017 Oct. Vol 77, Issue 4 pp 667-674.

- 2017 Strober, B, Bagel J, Lebwohl, M, et al. Efficacy and Safety of Apremilast in patients with moderate psoriasis and lower BSA: UNVEIL study. *JDD* 2017 Vol 16,28 pp 801-808.
- 2017 Bagel J, Tyring S, Rice KC, Collier DH, Kricorian G, Chung J, Iles J, Stolshek BS, Kaliyaperumal A, Papp KA. Open-label study of etanercept treatment in patients with moderate to severe plaque psoriasis who lost a satisfactory response to adalimumab. *Br J Dermatol*. 2017 Feb 14. doi: 10.1111/bjd.15381.
- 2017 Duffin KC, Papp KA, Bagel J, Levi E, Chen R, Gottlieb AB. Evaluation of the Physician Global Assessment and Body Surface Area Composite Tool for Assessing Psoriasis Response to Apremilast Therapy: Results from ESTEEM 1 and ESTEEM 2. *J Drugs Dermatol*. 2017;16(2):147-153.
- 2017 Armstrong AW, Siegel MP, Bagel J, Boh EE, Buell M, Cooper KD, Callis Duffin K, Eichenfield LF, Garg A, Gelfand JM, Gottlieb AB, Koo JY, Korman NJ, Krueger GG, Lebwohl MG, Leonardi CL, Mandelin AM, Menter MA, Merola JF, Pariser DM, Prussick RB, Ryan C, Shah KN, Weinberg JM, Williams MO, Wu JJ, Yamauchi PS, Van Voorhees AS. From the Medical Board of the National Psoriasis Foundation: Treatment targets for plaque psoriasis. *J Am Acad Dermatol*. 2017 Feb;76(2):290-298. doi: 10.1016/j.jaad.2016.10.017. Epub 2016 Nov 28.
- 2017 Callis Duffin K, Bagel J, Bukhalo M, Mercado Clement IJ, Choi SL, Zhao F, Gill A, Pangallo B, Shuler C, Mallbris L, Jackson K. Phase 3, open-label, randomized study of the pharmacokinetics, efficacy and safety of ixekizumab following subcutaneous administration using a prefilled syringe or an autoinjector in patients with moderate-to-severe plaque psoriasis (UNCOVER-A). *J Eur Acad Dermatol Venereol*. 2017 Jan;31(1):107-113. doi: 10.1111/jdv.13768. Epub 2016 Aug 8.
- 2016 Koo J, Tyring S, Werschler WP, Bruce S, Olesen M, Villumsen J, Bagel J. Superior efficacy of calcipotriene and betamethasone dipropionate aerosol foam versus ointment in patients with psoriasis vulgaris--A randomized phase II study. *J Dermatolog Treat*. 2016;27(2):120-7.
- 2016 Leonardi C, Bagel J, Yamauchi P, Pariser D, Xu Z, Moller A, Osterdal ML, Stein Gold L. The Aerosol Foam Formulation of the Fixed Combination Calcipotriene Plus Betamethasone Dipropionate Improves the Health-Related Quality of Life in Patients With Psoriasis Vulgaris: Results from the Randomized PSO-FAST Study. *J Drugs Dermatol*. 2016 Aug 1;15(8):981-7.
- 2016 Callis Duffin K, Bukhalo M, Bobonich MA, Shrom D, Zhao F, Kershner JR, Gill A, Pangallo B, Shuler CL, Bagel J. Usability of a novel

disposable autoinjector device for ixekizumab: results from a qualitative study and an open-label clinical trial, including patient-reported experience. *Med Devices* (Auckl). 2016 Oct 12;9:361-369.

- 2015 Leonardi C, Bagel J, Yamauchi P, Pariser D, Xu Z, Olesen M, Østerdal ML, Stein Gold L. Efficacy and Safety of Calcipotriene Plus Betamethasone Dipropionate Aerosol Foam in Patients With Psoriasis Vulgaris--a Randomized Phase III Study (PSO-FAST). *J Drugs Dermatol*. 2015 Dec;14(12):1468-77.
- 2015 Griffiths CE, Reich K, Lebwohl M, van de Kerkhof P, Paul C, Menter A, Cameron GS, Erickson J, Zhang L, Secrest RJ, Ball S, Braun DK, Osuntokun OO, Heffernan MP, Nickoloff BJ, Papp K; UNCOVER-2 and UNCOVER-3 investigators. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. *Lancet*. 2015 Aug 8;386(9993):541-51. doi: 10.1016/S0140-6736(15)60125-8. Epub 2015 Jun 10.
- 2015 Lebwohl M, Strober B, Menter A, Gordon K, Weglowska J, Puig L, Papp K, Spelman L, Toth D, Kerdel F, Armstrong AW, Stingl G, Kimball AB, Bachelez H, Wu JJ, Crowley J, Langley RG, Blicharski T, Paul C, Lacour JP, Tying S, Kircik L, Chimenti S, Callis Duffin K, Bagel J, Koo J, Aras G, Li J, Song W, Milmont CE, Shi Y, Erondur N, Klekotka P, Kotzin B, Nirula A. Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis. *N Engl J Med*. 2015 Oct;373(14):1318-28.
- 2015 Armstrong AW, Bagel J, Van Voorhees AS, Robertson AD, Yamauchi PS. Combining biologic therapies with other systemic treatments in psoriasis: evidence-based, best-practice recommendations from the Medical Board of the National Psoriasis Foundation. *JAMA Dermatol*. 2015 Apr;151(4):432-8.
- 2015 Yamauchi PS, Bagel J. Next-generation biologics in the management of plaque psoriasis: a literature review of IL-17 inhibition. *J Drugs Dermatol*. 2015 Mar;14(3):244-53.
- 2014 Bagel J, Levi E, Tying S, Knuckles ML. Real-life treatment profile of calcipotriene and betamethasone dipropionate topical suspension in patients with psoriasis vulgaris. *J Drugs Dermatol*. 2014 Nov;13(11):1374-9.
- 2014 Bagel, J. Biosimilars. *J Drugs Dermatol*. 2014 Jul;13(7):788-90.
- 2014 Hugh J, Van Voorhees AS, Nijhawan RI, Bagel J, Lebwohl M, Blauvelt A, Hsu S, Weinberg JM. From the Medical Board of the National Psoriasis Foundation: The risk of cardiovascular disease in individuals

- with psoriasis and the potential impact of current therapies. *J Am Acad Dermatol*. 2014 Jan;70(1):168-77.
- 2013 Kircik L, Lebwohl MG, Del Rosso JQ, Bagel J, Stein Gold L, Weiss JS. Clinical study results of desoximetasone spray, 0.25% in moderate to severe plaque psoriasis. *J Drugs Dermatol*. 2013 Dec;12(12):1404-10.
- 2013 Tyring S, Bagel J, Lynde C, Klekotka P, Thompson EH, Gandra SR, Shi Y, Kricorian G. Patient-reported outcomes in moderate-to-severe plaque psoriasis with scalp involvement: results from a randomized, double-blind, placebo-controlled study of etanercept. *J Eur Acad Dermatol Venereol*. 2013 Jan;27(1):125-8. doi: 10.1111/j.1468-3083.2011.04394.x. Epub 2011 Dec 21.
- 2012 Kimball AB, Alavian C, Alora-Palli M, Bagel J. Weight loss in obese patients with psoriasis can be successfully achieved during a course of phototherapy. *J Eur Acad Dermatol Venereol*. 2012 Dec;26(12):1582-4. doi: 10.1111/j.1468-3083.2011.04361.x. Epub 2011 Nov 30.
- 2012 Bagel J, Lynde C, Tyring S, Kricorian G, Shi Y, Klekotka P. Moderate to severe plaque psoriasis with scalp involvement: a randomized, double-blind, placebo-controlled study of etanercept. *J Am Acad Dermatol*. 2012 Jul;67(1):86-92.
- 2012 Hsu S, Papp KA, Lebwohl MG, Bagel J, Blauvelt A, Duffin KC, Crowley J, Eichenfield LF, Feldman SR, Fiorentino DF, Gelfand JM, Gottlieb AB, Jacobsen C, Kalb RE, Kavanaugh A, Korman NJ, Krueger GG, Michelon MA, Morison W, Ritchlin CT, Stein Gold L, Stone SP, Strober BE, Van Voorhees AS, Weiss SC, Wanat K, Bebo BF Jr. Consensus guidelines for the management of plaque psoriasis. *Arch Dermatol*. 2012 Jan;148(1):95-102. doi: 10.1001/archdermatol.2011.1410.
- 2011 Lapolla W, Yentzer BA, Bagel J, Halvorson CR, Feldman SR. A review of phototherapy protocols for psoriasis treatment. *J Am Acad Dermatol*. 2011 May;64(5):936-49. doi: 10.1016/j.jaad.2009.12.054. Epub 2011 Mar 22.
- 2011 Jerry Bagel, M.D. Adalimumab Plus Narrowband Ultraviolet B Light Phototherapy for the Treatment of Moderate to Severe Psoriasis, *Journal of Drugs in Dermatology*, April 2011.
- 2010 Zeichner JA, Lebwohl MG, Menter A, Bagel J, Del Rosso JQ, Elewski BE, Feldman SR, Kircik LH, Koo J, Gold LS, Tanghetti E; Psoriasis Process of Care Consensus Panel. Optimizing topical therapies for treating psoriasis: a consensus conference. *Cutis*. 2010 Sep;86(3 Suppl):5-31; quiz 32.
- 2010 Bagel, J. Treatment of Pediatric Psoriasis: Practical Dermatology, September 2010

- 2009 Bagel, J. Topical Therapies for the Treatment of Plaque Psoriasis: Cutaneous Medicine for the Practitioner, Vol. 84, No. 4S pgs. 3-13, October 2009
- 2009 Kalb RE, Bagel J, Korman NJ, Lebwohl MG, Young M, Horn EJ, Van Voorhees AS; National Psoriasis Foundation. Treatment of intertriginous psoriasis: From the Medical Board of National Psoriasis Foundation: J Am Acad Dermatology, 2009 January; 60 (1): pgs. 120-124
- 2009 Bagel, J. Understanding PML and Risks Associated with Biologic Therapies: *Practical Dermatology*, Vol. 6, No. 5 pgs. 26-27, May 2009.
- 2009 Bagel, J. Treatment of Effective Therapy: Lead Psoriasis Patients Along the Path to Clearance, *Practical Dermatology*, Vol. 6, No. 2, pgs. 42-47, February 2009.
- 2009 Bagel, J. LCD Plus NB-UVB reduces Time to Improvement of Psoriasis vs. NB-UVB Alone, *Journal of Drugs in Dermatology*, Vol. 8 Issue 4 April 2009.
- 2009 Kalb RE, Bagel J, Korman NJ, Lebwohl MG, Young M, Horn EJ, Van Voorhees AS; Treatment of intertriginous psoriasis: From the Medical Board of the National Psoriasis Foundation, *Journal of the American Academy of Dermatology*, Vol. 60, Issue 1, January, 2009.
- 2008 Bagel, J. Topical Psoriasis Therapy: Patients' Experiences, Physicians' Perceptions Don't Always Match, *Practical Dermatology*, Vol. 5, No. 2, pgs 58-61, February, 2008.
- 2008 Kircik L1, Bagel J, Korman N, Menter A, Elmets CA, Koo J, Yang YC, Chiou CF, Dann F, Stevens SR; Unite Study Group. Utilization of Narrow-Band Ultraviolet Light B Therapy and Etanercept for the Treatment of Psoriasis (UNITE): Efficacy, Safety, and Patient-Reported Outcomes, *Journal of Drugs in Dermatology*, January, 2008.
- 2008 Lebwohl M1, Bagel J, Gelfand JM, Gladman D, Gordon KB, Hsu S, Kalb RE, Kimball AB, Korman NJ, Krueger GG, Mease P, Morison WL, Paller A, Pariser DM, Ritchlin C, Strober B, Van Voorhees A, Weinstein GD, Young M, Horn L. From the Medical Board of the National Psoriasis Foundation: Monitoring and vaccinations in patients treated with biologics for psoriasis, *Journal of the American Academy of Dermatology*, Vol. 58, No. 1 pgs 94-105, January, 2008.
- 2007 Bagel, J. Be Prepared to Treat Pustular Psoriasis—An Uncommon Variant, *Practical Dermatology*, Vol. 4, No. 12, pg. 43, December, 2007.

- 2007 Bagel, J. Choosing the Safest Psoriasis Treatment for Women of Childbearing Potential, *Practical Dermatology*, Vol. 4, No. 11, pg. 50-51, November, 2007.
- 2007 Bagel, J. Effective Strategies To Treat Intertriginous Psoriasis, *Practical Dermatology*, Vol. 4, No. 10, pg. 54-58, October, 2007.
- 2007 Jerry Bagel, M.D., Responding to the Potential Effects of Obesity on Psoriasis, *Practical Dermatology*, Vol. 4, No. 9, pg. 46-47, September, 2007.
- 2007 Bagel, J. Building Long-Term Relationships as a Patient Caregiver, *Practical Dermatology*, Vol. 4, No. 8, pg. 53-54, August, 2007.
- 2007 Bagel, J. Get Familiar with the Biologics Safety Dance, *Practical Dermatology*, Vol. 4, No. 7, pg. 17-18, July, 2007.
- 2007 Bagel, J. Guidelines for Use of PUVA and Tips for Success, *Practical Dermatology*, Vol. 4, No. 6, pg. 56-57, June, 2007.
- 2007 Bagel, J. Psoriasis Research You and Your Patients Can Take to the Bank, *Practical Dermatology*, Vol. 4, No. 5, pg. 56-58, May, 2007.
- 2007 Bagel, J. Exploring Off-Label Use of Biologics for Dermatologic Indications, *Practical Dermatology*, Vol.4, No.5, pg.56-58. April, 2007.
- 2007 Bagel, J. et al., Assessment and tracking of long-term alefacept safety, *Journal of the American Academy of Dermatology*, Vol.56, Issue 2, Supplement2, February, 2007.
- 2007 Bagel, J. et al. National Psoriasis Foundation Clinical Consensus on Disease Severity, *Archives of Dermatology*, Vol. 143, February, 2007.
- 2007 Bagel, J. Evaluating the Risks and Benefits of Soriatane, *Practical Dermatology*, Vol. 4, No. 2, pg. 82-84, February, 2007.
- 2007 Bagel, J. New Perspectives on Methotrexate and Liver Biopsies, *Practical Dermatology*, Vol. 4, No. 1, pg. 74-75, January, 2007.
- 2006 Bagel, J. How and When to Use Cyclosporine in Psoriasis Care, *Practical Dermatology*, Vol.3, No. 12., pg. 58-61, December, 2006.
- 2006 Bagel, J. *Practical Dermatology*: In the Pipeline: Promising Early Data for a New Biologic. November, 2006: 3:11 pg. 25-26.
- 2006 Bagel, J. *Practical Dermatology*: Approaches to Difficult-to-Treat Psoriasis in Specialized Areas. October, 2006: 3:10 pg 48-50.
- 2006 Koo JY, Bagel J, Sweetser MT, Ticho BS. *Journal of Drugs in Dermatology*, Alefacept in combination with ultraviolet B phototherapy



- for the treatment of chronic plaque psoriasis: results from an open-label, multicenter study ( the “Manuscript”). July/August, 2006
- 2006 Bagel, J. Unlock the Benefits of Phototherapy for Psoriasis: *Practical Dermatology*, April, 2006: pg. 41
- 2005 Bagel, J. Psoriasis Combination Therapy: Psoriasis Forum
- 2005 Bagel, J. Decision points for the initiation of systemic treatment for psoriasis: *Journal of the American Academy of Dermatology*, 53:101, 2005
- 2005 Bagel, J. Chordoma Cutis: *Journal of the American Academy of Dermatology*, 52:S105, 2005
- 2002 Lowe NJ, Gonzalez J., Bagel, J., et al. Repeat courses of intravenous alefacept in patients with chronic plaque psoriasis provide consistent safety and efficacy. *Int J Dermatol* 2003;42:224-230.
- 2002 Bagel, J. A guide to Introducing Biologic Therapies for Psoriasis into Clinical Practice: Precept Medical Communications
- 2001 Ellis CN, Krueger GG; Alefacept Clinical Study Group.. Treatment of Chronic Plaque Psoriasis by Selective Targeting of Memory Effector T Lymphocytes: *New England Journal of Medicine*, 345:248, 2001
- 1999 Bagel, J. Establishing a Practical and Effective Psoriasis Treatment Center: *Dermatologic Clinics of North America*, April, 2000
- 1998 Bagel J, Garland WT, Breneman D, Holick M, Littlejohn TW, Crosby D, Faust H, Fivenson D, Nichols J. Administration of DAB389IL-2 to patients with recalcitrant psoriasis: A double-blind, phase II multicenter trial; *Journal of American Academy of Dermatology*, 38:938, 1998
- 1985 Bagel, J. Subcutaneous Nodules in Pseudomas Septicemia; *American Journal of Medicine*, 80:528, 1986
- 1985 Bagel, J. Hemorrhagic Bullae Associated with Morganella Morganii Septicemia; *Journal of the American Academy of Dermatology*, 12:575, 1985
- 1985 Bagel, J. Wavelength Dependence for 4', 5' – Monoadduct Formulation in UVA Irradiated 8-Methoxypsoralen and Calf Thymus DNA; *Photochemistry and Photobiology*, 42:95, 1985

### **SPEAKING BUREAU**

- 2008 - Present Speaker Bureau: Amgen, Abbvie, Janssen, Leo, Galderma, Stiefel, Eli Lilly, Novartis, Orth-Dermatologics.
- 2003-Present International Speaker including: Canada, Caribbean, Venezuela, Colombia, Argentina, France, Austria, Italy, Greece, Israel, Egypt.

### **MEDICAL EDITOR**

- 2006 Practical Dermatology
- 2010 Psoriasis Forum

### **HOSPITAL AFFILIATIONS**

University Medical Center at Princeton NJ – Senior Attending Physician

### **APPOINTMENTS**

- Present Clinical Associate Professor of Dermatology at Icahn School of Medicine at Mt Sinai.
- 2016-Present Adjunct Clinical Associate Professor of Dermatology at University of Pisa
- 2010-Present Co-Chair of Psoriasis Expert Resource Group.
- 2003-Present Teacher: Dermatology residents at College of Physicians and Surgeons of Columbia University
- 2003 - 2011 Clinical Associate Professor of Dermatology: College of Physicians and Surgeons of Columbia University.
- 2001 – Present Medical Advisory Board: National Psoriasis Foundation.
- 2008 - 2009 National Vitiligo Foundation Advisory Board
- 1975 - 1977 Teaching Assistant: Genetics and Biology Labs; Douglass College

### **FOREIGN LANGUAGES SPOKEN**

Italian, Yiddish, French

## **AWARDS**

2018 National Psoriasis Foundation: Excellence in Leadership Award  
2018 Inside Jersey: Top Doctor  
2017 Inside Jersey: Top Doctor  
2016 Mercer County Medical Society Award for Excellence in Research and Patient Advocacy  
2016 National Psoriasis Foundation: Outstanding Physician Clinician Award  
2016 American Academy of Dermatology: Presidential Citation  
2016 Inside Jersey: Top Doctor  
2015 Inside Jersey: Top Doctor  
2014 Inside Jersey: Top Doctor  
2013 Inside Jersey: Top Doctor  
2012 Inside Jersey: Top Doctor  
2011 Inside Jersey: Top Doctor  
2010 Inside Jersey: Top Doctor  
2009 Inside Jersey: Top Doctor  
2008 Patients' Choice Award  
2008 New York Metro Area: Top Doctor  
2007 New York Metro Area: Top Doctor  
2007 National Psoriasis Foundation Volunteer of the Year  
2006 President's Council Leader: National Psoriasis Foundation  
2006 New York Metro Area: Top Doctor  
2005 New Jersey Life: Doctor of the Year  
2005 New York Metro Area: Top Doctor  
2004 New York Metro Area: Top Doctor  
2003 New Jersey Magazine: Doctor of the Year  
2002 Golden Triangle Award  
2001 New Jersey Magazine: Doctor of the Year  
1997 Robert Wood Johnson Distinguished Volunteer Faculty Award

## **INTERESTS**

Italian  
Physical Fitness  
Baseball